Wolfgang A. Weber
Nuclear medicine physician who established PET response criteria and leads Munich's radiopharmaceutical development pipeline.
Overview
Wolfgang Weber led the early studies showing FDG-PET response after one cycle of chemotherapy predicts outcome in lung and gastro-oesophageal cancer and helped define PERCIST response criteria. He directs nuclear medicine at TUM, where PSMA ligands and FAP inhibitors were developed, and has been president of the Society of Nuclear Medicine and Molecular Imaging. His current focus is trial design for theranostics.
Similar pages
not linked directly; found by shared links- IdeaFAPI PET as the workup for MCED positives
- TechnologyFES PET (oestrogen receptor imaging)
Shares FAPI PET, FDG PET, PET (positron emission tomography).
- InstitutionCuranosticum Wiesbaden-Frankfurt
- PersonNeeta Pandit-Taskar
Shares Society of Nuclear Medicine and Molecular Imaging and the tag theranostics.
- IdeaUsing total-body PET's sensitivity to cut diagnostic tracer dose, not just scan time
Shares FDG PET and the tag imaging.
- InstitutionAll India Institute of Medical Sciences, New Delhi
- IndicationPancreatic ductal adenocarcinoma
- IdeaFAP-targeted radioligand therapy for sarcoma
Shares FAPI PET and the tag theranostics.